                         SEQUENCE LISTING

<110>  Novo Nordisk A/S
 
<120>  N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF

<130>  8465.204-WO

<150>  EP12157616.9
<151>  2012-03-01

<160>  1     

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X is a fatty acid with a length between 6 and 20 carbons

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Ala may be replaced by any other amino acid or is absent

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Ala may be replaced by any other amino acid or is absent

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Ala may be replaced by any other amino acid or is absent

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Ala may be replaced by any other amino acid or is absent

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Ala may be replaced by any other amino acid or is absent

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Ala may be replaced by any other amino acid or is absent

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Ala may be replaced by any other amino acid or is absent

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Ala may be replaced by any other amino acid

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Pro may be replaced by any other amino acid except Lys or Asp

<220>
<221>  VARIANT
<222>  (11)..(11)
<223>  Phe may be replaced by any other aromatic amino acid

<400>  1

Xaa Ala Ala Ala Ala Ala Ala Ala Ala Pro Phe 
1               5                   10      


